ASCENDIS PHARMA A/S - ADR (ASND)
US04351P1012 - ADR
Taking everything into account, ASND scores 3 out of 10 in our fundamental rating. ASND was compared to 588 industry peers in the Biotechnology industry. ASND may be in some trouble as it scores bad on both profitability and health. ASND shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
ASND had negative earnings in the past year.
In the past year ASND has reported a negative cash flow from operations.
In the past 5 years ASND always reported negative net income.
In the past 5 years ASND always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of ASND (-58.31%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.31% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-49.06%
ROA(5y)-44.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ASND has a Gross Margin of 83.36%. This is amongst the best in the industry. ASND outperforms 88.87% of its industry peers.
The Profit Margin and Operating Margin are not available for ASND so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 83.36% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ASND does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ASND has more shares outstanding
ASND has more shares outstanding than it did 5 years ago.
ASND has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -0.16, we must say that ASND is in the distress zone and has some risk of bankruptcy.
ASND has a Altman-Z score (-0.16) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.16 |
ROIC/WACCN/A
WACC6.65%
2.3 Liquidity
A Current Ratio of 3.56 indicates that ASND has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.56, ASND is doing worse than 60.10% of the companies in the same industry.
A Quick Ratio of 2.50 indicates that ASND has no problem at all paying its short term obligations.
ASND has a Quick ratio of 2.50. This is in the lower half of the industry: ASND underperforms 71.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.56 | ||
| Quick Ratio | 2.5 |
3. Growth
3.1 Past
ASND shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.69%, which is quite good.
ASND shows a strong growth in Revenue. In the last year, the Revenue has grown by 421.13%.
The Revenue has been growing by 90.68% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)17.69%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q58.38%
Revenue 1Y (TTM)421.13%
Revenue growth 3Y237.31%
Revenue growth 5Y90.68%
Revenue growth Q2Q501.32%
3.2 Future
ASND is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 37.09% yearly.
ASND is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 65.97% yearly.
EPS Next Y46.21%
EPS Next 2Y39.87%
EPS Next 3Y34.95%
EPS Next 5Y37.09%
Revenue Next Year98.29%
Revenue Next 2Y84%
Revenue Next 3Y76.2%
Revenue Next 5Y65.97%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
ASND reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ASND is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ASND's earnings are expected to grow with 34.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.87%
EPS Next 3Y34.95%
5. Dividend
5.1 Amount
No dividends for ASND!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ASCENDIS PHARMA A/S - ADR
NASDAQ:ASND (4/26/2024, 7:00:00 PM)
After market: 135.9 0 (0%)135.9
-1.03 (-0.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap7.69B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.31% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 83.36% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.56 | ||
| Quick Ratio | 2.5 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)17.69%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y46.21%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)421.13%
Revenue growth 3Y237.31%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y